Leading research team highlights role of SphygmoCor
Filed with ASX · · 2 pages · English
Story so far
Earlier from Conneqt Health
- FY2016 results
- Large national plan to reimburse SphygmoCor test
- $0.6 million pharmaceutical trial extension
- SphygmoCor selected for US publicly funded study
- US$1.1 million pharmaceutical contract
Later from Conneqt Health
- AtCor completes share placement
- Positive Novartis drug trial using SphygmoCor XCEL
- Tax refund
- Study Finds Central Aortic Waveform Improves HF Treatment
- AtCor Signs Local Health System Agreement
Follow Conneqt Health into a list and get an email when it puts out news.
Follow Conneqt Health